Mirikizumab in moderately to severely active ulcerative colitis: a profile of its use

Authors
Category Primary study
JournalDrugs and Therapy Perspectives
Year 2024
This article has no abstract
Epistemonikos ID: 81e619d951d2fc8f1f7b5cf9cf626e6603c6d6ff
First added on: Feb 19, 2025